Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer

NCT05804370 is registered in ClinicalTrials.gov with NX Development Corp as lead sponsor.

NCT NCT05804370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05804370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
Lead sponsor
NX Development Corp
Phase
Phase 3
Overall status
Recruiting
Start date
May 30, 2024
Completion date
May 31, 2029
Enrollment
170 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer